GPR55 ligands promote receptor coupling to multiple signalling pathways

Christopher M. Henstridge, Nariman Ab Balenga, Ralf Schröder, Julia K. Kargl, Wolfgang Platzer, Lene Martini, Simon Arthur, June Penman, Jennifer Whistler, Evi Kostenis, Maria Waldhoer, Andrew J. Irving

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Background and purpose: Although GPR55 is potently activated by the endogenous lysophospholipid, L-α-lysophosphatidylinositol (LPI), it is also thought to be sensitive to a number of cannabinoid ligands, including the prototypic CB1 receptor antagonists AM251 and SR141716A (Rimonabant ®). In this study we have used a range of functional assays to compare the pharmacological activity of selected cannabinoid ligands, AM251, AM281 and SR141716A with LPI in a HEK293 cell line engineered to stably express recombinant, human GPR55. Experimental approach: We evaluated Ca2+ signalling, stimulation of extracellular signal regulated kinase (ERK1/2) mitogen activated kinase MAP-kinases, induction of transcriptional regulators that are downstream of GPR55, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and cAMP response element binding protein (CREB), as well as receptor endocytosis. In addition, we assessed the suitability of a novel, label-free assay for GPR55 ligands that involves optical measurement of dynamic mass redistribution following receptor activation. Key results: GPR55 linked to a range of downstream signalling events and that the activity of GPR55 ligands was influenced by the functional assay employed, with differences in potency and efficacy observed. Conclusions and implications: Our data help to resolve some of the issues surrounding the pharmacology of cannabinoid ligands at GPR55 and highlight some differences in effector coupling associated with distinct GPR55 ligands.

Original languageEnglish (US)
Pages (from-to)604-614
Number of pages11
JournalBritish Journal of Pharmacology
Volume160
Issue number3
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

rimonabant
Ligands
Cannabinoids
Pharmacology
Lysophospholipids
NFATC Transcription Factors
TCF Transcription Factors
Cannabinoid Receptor CB1
Cyclic AMP Response Element-Binding Protein
HEK293 Cells
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase Kinases
Endocytosis
Mitogens
Cell Line

Keywords

  • Cannabinoid
  • GPCR
  • GPR55
  • LPI

ASJC Scopus subject areas

  • Pharmacology

Cite this

Henstridge, C. M., Balenga, N. A., Schröder, R., Kargl, J. K., Platzer, W., Martini, L., ... Irving, A. J. (2010). GPR55 ligands promote receptor coupling to multiple signalling pathways. British Journal of Pharmacology, 160(3), 604-614. https://doi.org/10.1111/j.1476-5381.2009.00625.x

GPR55 ligands promote receptor coupling to multiple signalling pathways. / Henstridge, Christopher M.; Balenga, Nariman Ab; Schröder, Ralf; Kargl, Julia K.; Platzer, Wolfgang; Martini, Lene; Arthur, Simon; Penman, June; Whistler, Jennifer; Kostenis, Evi; Waldhoer, Maria; Irving, Andrew J.

In: British Journal of Pharmacology, Vol. 160, No. 3, 01.01.2010, p. 604-614.

Research output: Contribution to journalArticle

Henstridge, CM, Balenga, NA, Schröder, R, Kargl, JK, Platzer, W, Martini, L, Arthur, S, Penman, J, Whistler, J, Kostenis, E, Waldhoer, M & Irving, AJ 2010, 'GPR55 ligands promote receptor coupling to multiple signalling pathways', British Journal of Pharmacology, vol. 160, no. 3, pp. 604-614. https://doi.org/10.1111/j.1476-5381.2009.00625.x
Henstridge CM, Balenga NA, Schröder R, Kargl JK, Platzer W, Martini L et al. GPR55 ligands promote receptor coupling to multiple signalling pathways. British Journal of Pharmacology. 2010 Jan 1;160(3):604-614. https://doi.org/10.1111/j.1476-5381.2009.00625.x
Henstridge, Christopher M. ; Balenga, Nariman Ab ; Schröder, Ralf ; Kargl, Julia K. ; Platzer, Wolfgang ; Martini, Lene ; Arthur, Simon ; Penman, June ; Whistler, Jennifer ; Kostenis, Evi ; Waldhoer, Maria ; Irving, Andrew J. / GPR55 ligands promote receptor coupling to multiple signalling pathways. In: British Journal of Pharmacology. 2010 ; Vol. 160, No. 3. pp. 604-614.
@article{fcf5a6d74feb45e7bdda7a55076e6576,
title = "GPR55 ligands promote receptor coupling to multiple signalling pathways",
abstract = "Background and purpose: Although GPR55 is potently activated by the endogenous lysophospholipid, L-α-lysophosphatidylinositol (LPI), it is also thought to be sensitive to a number of cannabinoid ligands, including the prototypic CB1 receptor antagonists AM251 and SR141716A (Rimonabant {\circledR}). In this study we have used a range of functional assays to compare the pharmacological activity of selected cannabinoid ligands, AM251, AM281 and SR141716A with LPI in a HEK293 cell line engineered to stably express recombinant, human GPR55. Experimental approach: We evaluated Ca2+ signalling, stimulation of extracellular signal regulated kinase (ERK1/2) mitogen activated kinase MAP-kinases, induction of transcriptional regulators that are downstream of GPR55, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and cAMP response element binding protein (CREB), as well as receptor endocytosis. In addition, we assessed the suitability of a novel, label-free assay for GPR55 ligands that involves optical measurement of dynamic mass redistribution following receptor activation. Key results: GPR55 linked to a range of downstream signalling events and that the activity of GPR55 ligands was influenced by the functional assay employed, with differences in potency and efficacy observed. Conclusions and implications: Our data help to resolve some of the issues surrounding the pharmacology of cannabinoid ligands at GPR55 and highlight some differences in effector coupling associated with distinct GPR55 ligands.",
keywords = "Cannabinoid, GPCR, GPR55, LPI",
author = "Henstridge, {Christopher M.} and Balenga, {Nariman Ab} and Ralf Schr{\"o}der and Kargl, {Julia K.} and Wolfgang Platzer and Lene Martini and Simon Arthur and June Penman and Jennifer Whistler and Evi Kostenis and Maria Waldhoer and Irving, {Andrew J.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1111/j.1476-5381.2009.00625.x",
language = "English (US)",
volume = "160",
pages = "604--614",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - GPR55 ligands promote receptor coupling to multiple signalling pathways

AU - Henstridge, Christopher M.

AU - Balenga, Nariman Ab

AU - Schröder, Ralf

AU - Kargl, Julia K.

AU - Platzer, Wolfgang

AU - Martini, Lene

AU - Arthur, Simon

AU - Penman, June

AU - Whistler, Jennifer

AU - Kostenis, Evi

AU - Waldhoer, Maria

AU - Irving, Andrew J.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background and purpose: Although GPR55 is potently activated by the endogenous lysophospholipid, L-α-lysophosphatidylinositol (LPI), it is also thought to be sensitive to a number of cannabinoid ligands, including the prototypic CB1 receptor antagonists AM251 and SR141716A (Rimonabant ®). In this study we have used a range of functional assays to compare the pharmacological activity of selected cannabinoid ligands, AM251, AM281 and SR141716A with LPI in a HEK293 cell line engineered to stably express recombinant, human GPR55. Experimental approach: We evaluated Ca2+ signalling, stimulation of extracellular signal regulated kinase (ERK1/2) mitogen activated kinase MAP-kinases, induction of transcriptional regulators that are downstream of GPR55, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and cAMP response element binding protein (CREB), as well as receptor endocytosis. In addition, we assessed the suitability of a novel, label-free assay for GPR55 ligands that involves optical measurement of dynamic mass redistribution following receptor activation. Key results: GPR55 linked to a range of downstream signalling events and that the activity of GPR55 ligands was influenced by the functional assay employed, with differences in potency and efficacy observed. Conclusions and implications: Our data help to resolve some of the issues surrounding the pharmacology of cannabinoid ligands at GPR55 and highlight some differences in effector coupling associated with distinct GPR55 ligands.

AB - Background and purpose: Although GPR55 is potently activated by the endogenous lysophospholipid, L-α-lysophosphatidylinositol (LPI), it is also thought to be sensitive to a number of cannabinoid ligands, including the prototypic CB1 receptor antagonists AM251 and SR141716A (Rimonabant ®). In this study we have used a range of functional assays to compare the pharmacological activity of selected cannabinoid ligands, AM251, AM281 and SR141716A with LPI in a HEK293 cell line engineered to stably express recombinant, human GPR55. Experimental approach: We evaluated Ca2+ signalling, stimulation of extracellular signal regulated kinase (ERK1/2) mitogen activated kinase MAP-kinases, induction of transcriptional regulators that are downstream of GPR55, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and cAMP response element binding protein (CREB), as well as receptor endocytosis. In addition, we assessed the suitability of a novel, label-free assay for GPR55 ligands that involves optical measurement of dynamic mass redistribution following receptor activation. Key results: GPR55 linked to a range of downstream signalling events and that the activity of GPR55 ligands was influenced by the functional assay employed, with differences in potency and efficacy observed. Conclusions and implications: Our data help to resolve some of the issues surrounding the pharmacology of cannabinoid ligands at GPR55 and highlight some differences in effector coupling associated with distinct GPR55 ligands.

KW - Cannabinoid

KW - GPCR

KW - GPR55

KW - LPI

UR - http://www.scopus.com/inward/record.url?scp=77952660029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952660029&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2009.00625.x

DO - 10.1111/j.1476-5381.2009.00625.x

M3 - Article

VL - 160

SP - 604

EP - 614

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 3

ER -